TLR3 (Toll-like receptor 3) variants and mutations
TLR3 (also known as Toll-like receptor 3) is a human protein-coding gene encoding a toll-like receptor 3 protein. It detects double-stranded RNA in endosomes and activates interferon and inflammatory programs important for antiviral defense. Loss-of-function variants can impair intrinsic immunity to herpes simplex virus in the central nervous system and predispose to herpes simplex encephalitis. This analysis covers 1,319 TLR3 variants and mutations. Of these, 79% have computational variant effect predictions. Disease context includes Herpetic encephalitis, hypothyroidism, and thyroid gland disorder. Example TLR3 variants include M1V, R2T, and T4A.
Variant analysis overview
- Gene: TLR3
- Protein: Toll-like receptor 3
- UniProt accession: O15455
- Organism: Homo sapiens
- Variants analyzed: 1319
- Variant scope: all variants
- Completed: 2026-08-19
Variant and mutation evidence
- Variant composition: 1,014 unspecified-consequence records; 132 missense variants; 24 frameshift variants; 135 synonymous variants; 8 stop-gained variants; 2 in-frame insertions; 2 in-frame deletions; 2 substitution
- Prediction scores: 1,043 variants have prediction scores (79% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: Herpetic encephalitis, hypothyroidism, thyroid gland disorder, Hashimoto thyroiditis, myxedema, HIV-1 infection, inborn error of immunity, autoimmune disease, autoimmune thyroid disease, basal cell carcinoma, age-related macular degeneration, myalgic encephalomeyelitis/chronic fatigue syndrome.
Protein structure and variant hotspots
- Protein features: 1 transmembrane segments; 3 domains; 17 post-translational modification sites.
- Structural context: 308 variants have structural context.
- PTM context: 33 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable TLR3 variants
Examples include M1V, R2T, T4A, T4T, L5A, L5F, L5C, P6L. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1V (p.Met1Val), rs776400293, ClinGen CA3161136, ClinVar RCV003847047, MetaLR 0.07, MetaSVM -1.08, Uncertain significance, Herpes simplex encephalitis, susceptibility to, 1
- R2T (p.Arg2Thr), NCI-TCGA TCGA novel, REVEL 0.04, MetaLR 0.05, Variant assessed as somatic; moderate impact.
- T4A (p.Thr4Ala), gnomAD 4-186076629-A-G, REVEL 0.05, MetaLR 0.03
- T4T (p.Thr4Thr), rs761878392, gnomAD 4-186076631-T-G, CADD 8.56
- L5A (p.Leu5Ala), rs1426283613, ClinGen CA792325154, ClinVar RCV002735910, Uncertain significance
- L5F (p.Leu5Phe), ExAC rs764928979, gnomAD rs764928979, REVEL 0.13, MetaLR 0.11
- L5C (p.Leu5Cys), gnomAD 4-186076630-CT-C, CADD 23.40
- P6L (p.Pro6Leu), rs2099302499, ClinGen CA359107121, ClinVar RCV001359457, TOPMed rs2099302499, REVEL 0.07, MetaLR 0.05, Uncertain significance, Herpes simplex encephalitis, susceptibility to, 1
- P6S (p.Pro6Ser), Ensembl rs2150066270, MetaLR 0.07, MetaSVM -0.99
- C7S (p.Cys7Ser), gnomAD rs2099302500, REVEL 0.08, MetaLR 0.05
- C7Y (p.Cys7Tyr), gnomAD 4-186076639-G-A, REVEL 0.14, MetaLR 0.02
- C7F (p.Cys7Phe), gnomAD 4-186076639-G-T, REVEL 0.12, MetaLR 0.04
- I8V (p.Ile8Val), gnomAD rs1480030311, REVEL 0.07, MetaLR 0.06
- I8N (p.Ile8Asn), gnomAD 4-186076642-T-A, REVEL 0.08, MetaLR 0.09
- I8I (p.Ile8Ile), rs192262541, gnomAD 4-186076643-C-T, CADD 3.75
- Y9C (p.Tyr9Cys), gnomAD rs1252260733, REVEL 0.09, MetaLR 0.06
- F10I (p.Phe10Ile), NCI-TCGA Cosmic COSV9971, MetaLR 0.05, MetaSVM -0.98, Variant assessed as somatic; moderate impact.
- W11* (p.Trp11Ter), ExAC rs750233576, TOPMed rs750233576, gnomAD rs750233576, CADD 34.00
- W11C (p.Trp11Cys), rs755127843, ClinGen CA3161143, ClinVar RCV003067728, ClinVar RCV004071670, REVEL 0.06, MetaLR 0.03, Uncertain significance, Herpes simplex encephalitis, susceptibility to, 1; not specified
- W11L (p.Trp11Leu), rs750233576, ClinGen CA359107157, ClinVar RCV003603958, REVEL 0.12, MetaLR 0.02, Uncertain significance, Herpes simplex encephalitis, susceptibility to, 1
- W11S (p.Trp11Ser), ExAC rs750233576, TOPMed rs750233576, gnomAD rs750233576, REVEL 0.12, MetaLR 0.04
- W11G (p.Trp11Gly), gnomAD 4-186076650-T-G, REVEL 0.12, MetaLR 0.04
- W11R (p.Trp11Arg), gnomAD 4-186076650-T-C, REVEL 0.12, MetaLR 0.04
- G12A (p.Gly12Ala), Ensembl rs2099302503, MetaLR 0.06, MetaSVM -1.00
- G12R (p.Gly12Arg), rs199539539, ClinGen CA3161144, ClinVar RCV000524712, 1000Genomes rs199539539, REVEL 0.18, MetaLR 0.04, Likely benign, Herpes simplex encephalitis, susceptibility to, 1
- G12E (p.Gly12Glu), gnomAD 4-186076654-G-A, REVEL 0.18, MetaLR 0.07
- G12G (p.Gly12Gly), gnomAD 4-186076655-G-A, CADD 6.40
- G13A (p.Gly13Ala), rs371978453, ClinGen CA3161146, ClinVar RCV002761639, ESP rs371978453, REVEL 0.08, MetaLR 0.06, Uncertain significance, Herpes simplex encephalitis, susceptibility to, 1
- G13C (p.Gly13Cys), gnomAD rs1470948740, REVEL 0.12, MetaLR 0.11, Uncertain significance, not specified
- G13D (p.Gly13Asp), rs371978453, ClinGen CA3161145, ClinVar RCV002028990, ESP rs371978453, REVEL 0.15, MetaLR 0.11, Uncertain significance, Herpes simplex encephalitis, susceptibility to, 1
- G13S (p.Gly13Ser), gnomAD rs1470948740, REVEL 0.07, MetaLR 0.06
- G13R (p.Gly13Arg), gnomAD 4-186076656-G-C, REVEL 0.12, MetaLR 0.07
- G13V (p.Gly13Val), gnomAD 4-186076657-G-T, REVEL 0.10, MetaLR 0.06
- G13G (p.Gly13Gly), rs369957478, gnomAD 4-186076658-C-A, CADD 1.50
- L14P (p.Leu14Pro), ExAC rs746264502, TOPMed rs746264502, gnomAD rs746264502, REVEL 0.24, MetaLR 0.13, Uncertain significance, not specified
- L14L (p.Leu14Leu), gnomAD 4-186076661-T-A, CADD 7.08
- L15W (p.Leu15Trp), rs149602022, ClinGen CA3161151, ClinVar RCV000886990, 1000Genomes rs149602022, REVEL 0.08, MetaLR 0.07, Likely benign, Herpes simplex encephalitis, susceptibility to, 1
- L15C (p.Leu15Cys), gnomAD 4-186076659-CT-C, CADD 24.80
- L15L (p.Leu15Leu), rs374004299, gnomAD 4-186076664-G-A, CADD 6.41
- P16S (p.Pro16Ser), gnomAD 4-186076665-C-T, REVEL 0.02, MetaLR 0.05
- P16P (p.Pro16Pro), gnomAD 4-186076667-C-T, CADD 7.54
- F17L (p.Phe17Leu), ExAC rs746697955, TOPMed rs746697955, gnomAD rs746697955, REVEL 0.04, MetaLR 0.02, Uncertain significance, Herpes simplex encephalitis, susceptibility to, 1
- G18E (p.Gly18Glu), Ensembl rs2099302507, MetaLR 0.05, MetaSVM -1.05
- G18R (p.Gly18Arg), gnomAD rs1283113945, REVEL 0.13, MetaLR 0.05
- G18G (p.Gly18Gly), rs768048228, gnomAD 4-186076673-G-A, CADD 7.66
- M19I (p.Met19Ile), Ensembl rs2099302508, MetaLR 0.02, MetaSVM -1.03
- M19L (p.Met19Leu), ExAC rs776263129, gnomAD rs776263129, REVEL 0.03, MetaLR 0.04
- M19V (p.Met19Val), ExAC rs776263129, gnomAD rs776263129, REVEL 0.02, MetaLR 0.05
- L20M (p.Leu20Met), TOPMed rs1561370121, MetaLR 0.08, MetaSVM -1.03
- C21R (p.Cys21Arg), rs1279991080, ClinGen CA359107211, ClinVar RCV003838030, gnomAD rs1279991080, REVEL 0.16, MetaLR 0.11, Uncertain significance, Herpes simplex encephalitis, susceptibility to, 1
- C21Y (p.Cys21Tyr), TOPMed rs2099302510, MetaLR 0.08, MetaSVM -1.00
- A22V (p.Ala22Val), gnomAD 4-186076684-C-T, REVEL 0.04, MetaLR 0.05
- A22A (p.Ala22Ala), rs146166844, gnomAD 4-186076685-A-G, CADD 0.24
- S23F (p.Ser23Phe), ExAC rs769776186, gnomAD rs769776186, REVEL 0.20, MetaLR 0.09
- S23P (p.Ser23Pro), Ensembl rs2150066292, MetaLR 0.10, MetaSVM -1.04
- S23S (p.Ser23Ser), rs1252524431, gnomAD 4-186076688-C-T, CADD 3.63
- S24F (p.Ser24Phe), rs772953712, ClinGen CA3161158, ClinVar RCV000801422, ClinVar RCV004792488, REVEL 0.21, MetaLR 0.12, Uncertain significance, not provided; Herpes simplex encephalitis, susceptibility to, 1
- S24S (p.Ser24Ser), rs762762392, gnomAD 4-186076691-C-T, CADD 0.57
- T25I (p.Thr25Ile), Ensembl rs2099302512, REVEL 0.03, MetaLR 0.06
- T25S (p.Thr25Ser), Ensembl rs2150066296, REVEL 0.04, MetaLR 0.05
- T26I (p.Thr26Ile), TOPMed rs2099302514, MetaLR 0.04, MetaSVM -1.04
- T26A (p.Thr26Ala), gnomAD 4-186076695-A-G, REVEL 0.08, MetaLR 0.03
- T26T (p.Thr26Thr), gnomAD 4-186076697-C-T, CADD 3.15
- K27N (p.Lys27Asn), TOPMed rs1188065402, gnomAD rs1188065402, REVEL 0.03, MetaLR 0.06
- K27K (p.Lys27Lys), rs1188065402, gnomAD 4-186076700-G-A, CADD 0.99
- C28G (p.Cys28Gly), ExAC rs766214573, TOPMed rs766214573, gnomAD rs766214573, REVEL 0.73, MetaLR 0.77
- C28C (p.Cys28Cys), gnomAD 4-186076703-C-T, CADD 3.76
- T29I (p.Thr29Ile), rs2099302516, ClinGen CA359107266, ClinVar RCV001318314, Ensembl rs2099302516, AlphaMissense 0.08, MetaLR 0.10, Uncertain significance, Herpes simplex encephalitis, susceptibility to, 1
- T29P (p.Thr29Pro), gnomAD 4-186076704-A-C, REVEL 0.10, MetaLR 0.12
- V30G (p.Val30Gly), rs929907117, ClinGen CA112539628, ClinVar RCV003873093, TOPMed rs929907117, REVEL 0.34, MetaLR 0.11, Uncertain significance, Herpes simplex encephalitis, susceptibility to, 1
- V30V (p.Val30Val), rs2099302517, gnomAD 4-186076709-T-C, CADD 1.41
- S31T (p.Ser31Thr), Ensembl rs2150066300, MetaLR 0.08, MetaSVM -1.03
- S31I (p.Ser31Ile), gnomAD 4-186076711-G-T, REVEL 0.15, MetaLR 0.12
- S31S (p.Ser31Ser), rs1245191986, gnomAD 4-186076712-C-T, CADD 0.35
- H32P (p.His32Pro), gnomAD 4-186076714-A-C, REVEL 0.15, MetaLR 0.06
- H32R (p.His32Arg), gnomAD 4-186076714-A-G, REVEL 0.08, MetaLR 0.07
- H32H (p.His32His), gnomAD 4-186076715-T-C, CADD 0.03
- E33* (p.Glu33Ter), TOPMed rs1406608445
- E33D (p.Glu33Asp), TOPMed rs1481297372, gnomAD rs1481297372, REVEL 0.03, MetaLR 0.05
- E33E (p.Glu33Glu), rs1481297372, gnomAD 4-186076718-A-G, CADD 2.33
- V34I (p.Val34Ile), TOPMed rs1327768627
- V34L (p.Val34Leu), TOPMed rs1327768627, MetaLR 0.06, MetaSVM -1.00
- V34A (p.Val34Ala), gnomAD 4-186076720-T-C, REVEL 0.07, MetaLR 0.05
- A35S (p.Ala35Ser), gnomAD 4-186076722-G-T, REVEL 0.29, MetaLR 0.20
- A35T (p.Ala35Thr), gnomAD 4-186076722-G-A, REVEL 0.34, MetaLR 0.16
- D36H (p.Asp36His), gnomAD 4-186076725-G-C, REVEL 0.61, MetaLR 0.42
- C37* (p.Cys37Ter), ExAC rs761011950, TOPMed rs761011950
- C37R (p.Cys37Arg), rs752889035, ClinGen CA3161161, ClinVar RCV001228863, ClinVar RCV005394844, REVEL 0.75, MetaLR 0.53, Uncertain significance, Immunodeficiency 83, susceptibility to viral infections; Herpes simplex encephal
- S38G (p.Ser38Gly), rs1418733023, NCI-TCGA Cosmic COSV9971, gnomAD rs1418733023, REVEL 0.38, MetaLR 0.29, Variant assessed as somatic; moderate impact.
- H39P (p.His39Pro), gnomAD rs1426637668, MetaLR 0.23, MetaSVM -0.66
- H39Q (p.His39Gln), gnomAD rs1168473085, REVEL 0.28, MetaLR 0.10
- H39R (p.His39Arg), gnomAD rs1426637668, REVEL 0.29, MetaLR 0.06
- L40R (p.Leu40Arg), gnomAD rs1356345714, REVEL 0.24, MetaLR 0.04
- L40V (p.Leu40Val), gnomAD 4-186076737-C-G, REVEL 0.17, MetaLR 0.12
- L40P (p.Leu40Pro), gnomAD 4-186076738-T-C, REVEL 0.31, MetaLR 0.22
- L40L (p.Leu40Leu), gnomAD 4-186076739-G-A, CADD 4.88
- K41R (p.Lys41Arg), gnomAD 4-186076741-A-G, REVEL 0.21, MetaLR 0.28
- K41K (p.Lys41Lys), rs1430424244, gnomAD 4-186076742-G-A, CADD 6.56
- L42F (p.Leu42Phe), ExAC rs764017833, TOPMed rs764017833, gnomAD rs764017833, REVEL 0.53, MetaLR 0.42
- T43S (p.Thr43Ser), gnomAD 4-186076747-C-G, REVEL 0.32, MetaLR 0.34
- T43T (p.Thr43Thr), gnomAD 4-186076748-T-C, CADD 3.32
- Q44E (p.Gln44Glu), gnomAD rs1363903820, REVEL 0.11, MetaLR 0.05
- Q44K (p.Gln44Lys), gnomAD 4-186076749-C-A, REVEL 0.05, MetaLR 0.07
- Q44* (p.Gln44Ter), gnomAD 4-186076749-C-T, CADD 34.00
- Q44H (p.Gln44His), gnomAD 4-186076751-G-C, REVEL 0.02, MetaLR 0.05
- V45E (p.Val45Glu), gnomAD rs2099302521, REVEL 0.43, MetaLR 0.35
- V45L (p.Val45Leu), Ensembl rs1561370160, REVEL 0.17, MetaLR 0.13
- P46R (p.Pro46Arg), NCI-TCGA Cosmic COSV9971, MetaLR 0.66, MetaSVM 0.62, Variant assessed as somatic; moderate impact.
- P46P (p.Pro46Pro), rs267600111, gnomAD 4-186076757-C-G, CADD 0.10
- D47E (p.Asp47Glu), gnomAD rs780586678, REVEL 0.06, MetaLR 0.06
- D47H (p.Asp47His), ExAC rs757662803, TOPMed rs757662803, gnomAD rs757662803, MetaLR 0.08, MetaSVM -1.04, Uncertain significance
- D47N (p.Asp47Asn), rs757662803, ClinGen CA3161165, ClinVar RCV001935682, ClinVar RCV003948818, REVEL 0.11, MetaLR 0.07, Uncertain significance, Herpes simplex encephalitis, susceptibility to, 1
- D47V (p.Asp47Val), rs770261956, ClinGen CA3161166, ClinVar RCV001886061, ClinVar RCV004041081, REVEL 0.07, MetaLR 0.09, Uncertain significance, not specified; not provided; Herpes simplex encephalitis, susceptibility to, 1
- D47G (p.Asp47Gly), gnomAD 4-186076759-A-G, REVEL 0.06, MetaLR 0.08
- D48G (p.Asp48Gly), TOPMed rs1047312739, gnomAD rs1047312739, MetaLR 0.05, MetaSVM -1.10
- D48V (p.Asp48Val), TOPMed rs1047312739, gnomAD rs1047312739, REVEL 0.53, MetaLR 0.23
- L49Q (p.Leu49Gln), TOPMed rs1489675622, gnomAD rs1489675622, REVEL 0.63, MetaLR 0.45
- L49P (p.Leu49Pro), gnomAD 4-186076765-T-C, REVEL 0.69, MetaLR 0.45
- L49L (p.Leu49Leu), gnomAD 4-186076766-A-G, CADD 0.76
- P50S (p.Pro50Ser), gnomAD rs1297171122, REVEL 0.62, MetaLR 0.52
- P50T (p.Pro50Thr), NCI-TCGA Cosmic COSV9971, MetaLR 0.61, MetaSVM 0.40, Variant assessed as somatic; moderate impact.
- P50H (p.Pro50His), gnomAD 4-186076768-C-A, REVEL 0.71, MetaLR 0.68
- T51R (p.Thr51Arg), gnomAD rs1342269987, REVEL 0.03, MetaLR 0.07
- N52D (p.Asn52Asp), rs2478210355, ClinGen CA359107414, ClinVar RCV002970937, REVEL 0.13, MetaLR 0.12, Uncertain significance, Herpes simplex encephalitis, susceptibility to, 1
- N52N (p.Asn52Asn), gnomAD 4-186076775-C-T, CADD 5.93
- I53L (p.Ile53Leu), rs1221000109, ClinGen CA359107421, ClinVar RCV001056449, TOPMed rs1221000109, REVEL 0.20, MetaLR 0.15, Uncertain significance, Herpes simplex encephalitis, susceptibility to, 1
- I53T (p.Ile53Thr), NCI-TCGA Cosmic COSV5717, Variant assessed as somatic; moderate impact.
- I53V (p.Ile53Val), rs1221000109, ClinGen CA359107422, ClinVar RCV002712149, TOPMed rs1221000109, REVEL 0.26, MetaLR 0.33, Uncertain significance, Herpes simplex encephalitis, susceptibility to, 1
- T54A (p.Thr54Ala), Ensembl rs2150066317, REVEL 0.25, MetaLR 0.20
- T54K (p.Thr54Lys), ExAC rs751015522, TOPMed rs751015522, gnomAD rs751015522, REVEL 0.20, MetaLR 0.10, Uncertain significance, not specified; Herpes simplex encephalitis, susceptibility to, 1
- T54R (p.Thr54Arg), ExAC rs751015522, TOPMed rs751015522, gnomAD rs751015522, REVEL 0.30, MetaLR 0.19
- T54T (p.Thr54Thr), rs1490723082, gnomAD 4-186076781-A-G, CADD 0.29
- V55L (p.Val55Leu), gnomAD rs1222090489, REVEL 0.05, MetaLR 0.09
- V55V (p.Val55Val), rs139854420, gnomAD 4-186076784-G-A, CADD 5.42
- L56L (p.Leu56Leu), gnomAD 4-186076785-T-C, CADD 1.67
- L56S (p.Leu56Ser), gnomAD 4-186076786-T-C, REVEL 0.83, MetaLR 0.82
- N57K (p.Asn57Lys), ESP rs376119293, TOPMed rs376119293, gnomAD rs376119293, REVEL 0.18, MetaLR 0.13, Uncertain significance, Herpes simplex encephalitis, susceptibility to, 1
- N57S (p.Asn57Ser), Ensembl rs2150066323
- N57N (p.Asn57Asn), gnomAD 4-186076790-C-T, CADD 5.62
- L58P (p.Leu58Pro), TOPMed rs2099302524
- L58F (p.Leu58Phe), gnomAD 4-186076791-C-T, REVEL 0.52, MetaLR 0.57
- L58L (p.Leu58Leu), rs780632564, gnomAD 4-186076793-T-C, CADD 4.89
- T59I (p.Thr59Ile), 1000Genomes rs143307508, ESP rs143307508, ExAC rs143307508, TOPMed rs143307508, Uncertain significance
- T59N (p.Thr59Asn), rs143307508, ClinGen CA3161170, ClinVar RCV000690308, ClinVar RCV002499225, REVEL 0.13, MetaLR 0.12, Uncertain significance, Susceptibility to HIV infection; Immunodeficiency 83, susceptibility to viral in
- T59T (p.Thr59Thr), rs768368875, gnomAD 4-186076796-C-T, CADD 7.45
- H60Q (p.His60Gln), rs780502519, ClinGen CA3161172, ClinVar RCV003604211, ClinVar RCV004371669, REVEL 0.28, MetaLR 0.18, Uncertain significance, not specified; Herpes simplex encephalitis, susceptibility to, 1
- H60Y (p.His60Tyr), Ensembl rs2099302526
- N61K (p.Asn61Lys), ExAC rs747726110, gnomAD rs747726110, REVEL 0.62, MetaLR 0.66
- Q62E (p.Gln62Glu), NCI-TCGA Cosmic COSV5716, REVEL 0.08, MetaLR 0.11, Variant assessed as somatic; moderate impact.
- Q62Q (p.Gln62Gln), rs1579727099, gnomAD 4-186076805-A-G, CADD 7.06
- L63F (p.Leu63Phe), NCI-TCGA Cosmic COSV5716, REVEL 0.20, MetaLR 0.33, Variant assessed as somatic; moderate impact.
- R64G (p.Arg64Gly), Ensembl rs2099302528, Uncertain significance, Herpes simplex encephalitis, susceptibility to, 1
- R64K (p.Arg64Lys), ExAC rs769571674, TOPMed rs769571674, gnomAD rs769571674
- R65G (p.Arg65Gly), TOPMed rs1426754278, gnomAD rs1426754278, REVEL 0.16, MetaLR 0.15, Likely benign
- R65R (p.Arg65Arg), rs1426754278, gnomAD 4-186076812-A-C, CADD 7.64
- L66F (p.Leu66Phe), TOPMed rs934375780, gnomAD rs934375780
- L66S (p.Leu66Ser), gnomAD rs1344959698, REVEL 0.68, MetaLR 0.73
- L66L (p.Leu66Leu), gnomAD 4-186076815-T-C, CADD 2.13
- L66* (p.Leu66Ter), gnomAD 4-186076816-T-G, CADD 35.00
- P67S (p.Pro67Ser), gnomAD 4-186076818-C-T, REVEL 0.44, MetaLR 0.51
- A68A (p.Ala68Ala), rs201229975, gnomAD 4-186076823-C-T, CADD 0.64
- A69S (p.Ala69Ser), ExAC rs762922535, TOPMed rs762922535, gnomAD rs762922535, REVEL 0.08, MetaLR 0.17, Uncertain significance
- A69T (p.Ala69Thr), rs762922535, ClinGen CA3161176, ClinVar RCV000824342, ExAC rs762922535, REVEL 0.07, MetaLR 0.26, Uncertain significance, Herpes simplex encephalitis, susceptibility to, 1
- A69V (p.Ala69Val), gnomAD 4-186076825-C-T, REVEL 0.09, MetaLR 0.31
- N70S (p.Asn70Ser), ExAC rs774142858, gnomAD rs774142858, REVEL 0.19, MetaLR 0.16
- N70K (p.Asn70Lys), gnomAD 4-186076829-C-A, REVEL 0.29, MetaLR 0.41
- T72I (p.Thr72Ile), ExAC rs760739824, gnomAD rs760739824, REVEL 0.28, MetaLR 0.38
- T72K (p.Thr72Lys), gnomAD 4-186076834-C-A, REVEL 0.30, MetaLR 0.23
- T72T (p.Thr72Thr), gnomAD 4-186076835-A-G, CADD 5.21
- R73K (p.Arg73Lys), Ensembl rs2150066339
- R73S (p.Arg73Ser), TOPMed rs2099302532, gnomAD rs2099302532, REVEL 0.23, MetaLR 0.23
- Y74C (p.Tyr74Cys), NCI-TCGA TCGA novel, Uncertain significance, Herpes simplex encephalitis, susceptibility to, 1
- Y74N (p.Tyr74Asn), gnomAD 4-186076839-T-A, REVEL 0.71, MetaLR 0.59
- Y74H (p.Tyr74His), gnomAD 4-186076839-T-C, REVEL 0.68, MetaLR 0.60
- S75N (p.Ser75Asn), Ensembl rs1579727130
- S75S (p.Ser75Ser), gnomAD 4-186076844-C-T, CADD 1.07
- S75R (p.Ser75Arg), gnomAD 4-186076844-C-A, REVEL 0.05, MetaLR 0.08
- Q76H (p.Gln76His), TOPMed rs1415392304, gnomAD rs1415392304, REVEL 0.19, MetaLR 0.08
- L77V (p.Leu77Val), gnomAD 4-186076848-C-G, REVEL 0.59, MetaLR 0.71
- L77L (p.Leu77Leu), rs2099302535, gnomAD 4-186076848-C-T, CADD 4.97
Public TLR3 analysis runs
- TLR3 analysis run — TLR3 (1,319 variants) — completed 2026-08-19